Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started

Description

Summary

This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.

Official Title

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)

Details

This study will not exceed 100 participants. Participants will be reevaluated annually to assess the treatment benefit of zalifrelimab and/or balstilimab and thereby, continued eligibility for treatment. Under this program, treatment will be continued with balstilimab, as either monotherapy or as used in combination therapy with zalifrelimab, for participants that have previously received one or both of these investigational medicinal products in a clinical study.

Keywords

Cancer, Balstilimab, AGEN2034, Zalifrelimab, AGEN1884, Monotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.

You CAN'T join if...

Locations

  • University of California, San Francisco Medical Center not accepting new patients
    San Francisco California 94158 United States
  • Hoag Gynecologic Oncology not accepting new patients
    Newport Beach California 92663 United States

Details

Status
not accepting new patients
Start Date
Sponsor
Agenus Inc.
ID
NCT05572970
Study Type
Expanded Access
Last Updated